VARUBI Assets of Tesaro, Inc.

Tesaro, Inc. is a biotechnology company focused on the development and commercialization of innovative cancer therapies, emphasizing PARP inhibitors to improve patient outcomes in oncology. Founded in 2015 in Waltham, US, Tesaro, Inc. specializes in oncology treatments.

In June 2018, TerSera Therapeutics LLC acquired the VARUBI Assets of Tesaro, Inc. for USD 40. 00 mn. The acquisition included an initial payment of USD 35.

00 mn at closing and USD 5. 00 mn eighteen months later. The deal was completed in July 2018. The founder's specific history was not provided.

Tesaro, an oncology-focused company acquired by GSK, specializes in the development and commercialization of innovative cancer treatments, particularly in the area of PARP inhibitors. Its flagship product, Niraparib, is designed to treat patients with ovarian cancer, specifically those with homologous recombination deficiency (HRD) or BRCA mutations. This targeted therapy functions by inhibiting the enzyme poly(ADP-ribose) polymerase (PARP), thereby preventing cancer cells from repairing their DNA, ultimately leading to cell death. Tesaro also emphasizes the importance of PARP inhibitors in expanding treatment options for various cancer types beyond ovarian cancer, ultimately aiming to improve patient outcomes.

Tesaro's products are marketed primarily in the United States and Europe, addressing the needs of oncologists and healthcare providers treating cancer patients. Tesaro generates revenue through the sales of its oncology products, notably through direct-to-consumer channels as well as partnerships with healthcare institutions and oncology practices. The revenue structure involves pricing agreements with hospitals and clinics, allowing for bulk purchasing of its therapies, particularly Niraparib. These transactions are typically structured as B2B agreements, where healthcare providers procure the treatments to offer to patients in their care.

Pricing plans for these therapies are established within the healthcare market, reflecting the value provided to patients in managing their cancer treatment. The company is committed to ensuring access to its innovative therapies, thereby maintaining a focus on patient and healthcare provider needs in its revenue generation strategies. Following the acquisition of the VARUBI Assets in July 2018, Tesaro aims to leverage its resources for future product development and expansion. While the company’s specific upcoming products and their launch dates have not been disclosed, it is anticipated that recent funding from the acquisition will bolster its research and development efforts.

Tesaro plans to explore new markets, particularly in Europe and Asia, for the distribution of its oncology products, utilizing the acquired assets to enhance its market presence by 2025.